Wednesday, June 27, 2012

Settlement on Yaz & Yasmin

Last month it was reported from Bloomberg News that Bayer AG, the largest drug manufacturer in Germany, agreed to at least a $100 million settlement to resolve about 500 lawsuits involving their contraceptive medications, Yaz and Yasmin. The settlement is a result of a few years of litigation set forth by women who claimed Yaz and Yasmin were the cause their Deep Vein Thrombosis or Pulmonary Embolism.

Approximately $220,000 per case is the reported amount required by Bayer to settle each case claiming Yaz and Yasmin as the cause of blood clots. Sometimes fatal, the clots may also cause heart attacks and strokes.

If you or a loved one suffered an injury as a result of taking Yaz, Yasmin or Ocella, you may be entitled to compensation. Reported injuries associated with these medications have been heart attacks, strokes, gall bladder disease, pulmonary embolisms,and deep vein thrombosis. The time to file a claim is ending soon so contact us now for a free claim evaluation at defectivemedications@gmail.com

"LIKE" us on facebook http://www.facebook.com/DefectiveMedications

Monday, June 18, 2012

Pradaxa and Internal Bleeding

Pradaxa, a blood thinning medication prescribed to treat blood clots, has come under fire for allegations that it is causing serious internal bleeding events in patients. In some cases, the bleeding events have resulted in death as there is no reversal agent to counteract the drug. Over 200 deaths have been reported in direct relation to the use of Pradaxa. Unlike Warfarin and other blood thinning medications there is no protocol to resume immediate clotting when using Pradaxa in such circumstances.

Bleeding events can include the following:

-Gastrointestinal Bleeding
-Spontaneous Internal Bleeding
-Hemorrhagic Stroke (Bleeding on the brain.)
-Excessive bleeding after trauma.

A recent study has also linked Pradaxa use to an increased risk of heart attack and acute coronary syndrome by 33% over the use of Warfarin and placebos. Lawsuits have already been filed and many more are pending.The lawyers filing suits allege that the injured plaintiffs have experienced severe side-effects as a result of using Pradaxa, and were unaware of these certain risks.

Like us on facebook at http://www.facebook.com/DefectiveMedications

Yaz Side Effects Lawsuit

Women who have suffered from any of the following injuries may have a claim and be entitled to financial compensation.

*Pulmonary Embolism
*Deep Vein Thrombosis
*Heart Attack
*Stroke
*Gallbladder Disease

Lawsuits that have already been filed allege that Bayer Pharmaceuticals, the maker of Yaz and Yasmin, did not conduct sufficient research on the medication and failed to perform a recall after post-marketing reports identified a risk of life threatening conditions. The suits also allege that Bayer Pharmaceuticals insufficiently warned of the risks of Yaz and Yasmin in an effort produce comfort among consumers.

The U.S. Food and Drug Administration (FDA) Adverse Events reporting system indicated serious side effects of using Yaz, Yasmin and Ocella including but not limited to heart arrhythmias, stroke, gallbladder problems, blood clots, embolisms and sudden death following the use of the medications.
Drospirenone, a type of progestin used in the oral contraceptives Yaz and Yasmin, is a significant contributing factor in the injuries associated with the medications. It can cause elevated levels of potassium which can lead to serious heart conditions and other concerns.

We are reviewing claims of injuries associated with Yaz, Yasmin and Ocella. If you or a loved has suffered any of the listed side effects contact us today for a free claim evaluation.

Like us on facebook at http://www.facebook.com/DefectiveMedications

Wednesday, June 13, 2012

Yaz and Yasmin Lawsuit


Bayer settled over 600 lawsuits alleging injuries were sustained from its popular oral contraceptives Yaz and Yasmin. The injuries include but are not limited togall bladder disease, stroke, blood clots, embolisms, and in severe cases death.

Inits 2011 Annual Report, Bayer admits to settling 70 Yaz and Yasmin lawsuits. According to the report, attorneys for the plaitiffs and Bayer reached agreements, without admission of liability, to settle the 70 claims.

The initial bellwether trial, scheduled to commence January 9, 2012, has been delayed until further order from the court. Judge Herndon, the judge overseeing the litigation, would like to allow the parties additional time to settle a near 6,000 lawsuits related to Yaz and Yasmin. The suits claim the drugs are responsible for injuries to patients that include pulmonary embolisms (PE), deep vein thrombosis (DVT), and strokes.

Tuesday, June 12, 2012

Recently, Bloomberg news reported on an announcement from Bayer saying that it has settled 651 cases where the plaintiff is alleging that its birth control medications, Yaz and Yasmin, were the cause fatal of blood clots that can lead to deep vein thrombosis, pulmonary embolisms, heart attacks and strokes. Bayer claims the company has paid $142 million in the settlements, averaging roughly $218,000 per case.

Bayer also states the drug manufacturer “is only settling U.S. patient claims for venous clot injuries (deep vein thrombosis or pulmonary embolism) after a case specific analysis of medical records.”

An April 13, 2012 report from Bloomberg statesBayer has agreed to settle the first 500 suits for around $110 million. According to this report, the settlement update surfaced less than two weeks after JPMorgan Chase & Co analyst, Richard Vosser, said Bayer may have to pay more than $2.65 billion to settle all cases related to Yaz and Yasmin. The line-up of contraceptives spurred $1.85 billion in 2010.

If you or a loved one suffered an injury as a result of taking Yaz, Yasmin or Ocella, you may be entitled to compensation. Reported injuries associated with these medications have been heart attacks, strokes, gall bladder disease, pulmonary embolisms, and deep vein thrombosis. The time to file a claim is ending soon so contact us now for a free claim evaluation.